DocMorris raises 2026 guidance following strong H1 growth

DocMorris AG has reported strong growth for the first half of 2026, leading the company to raise its full-year guidance for revenue and adjusted EBITDA. External revenue rose 12.5% year-on-year to CHF 627.8 million, driven significantly by a 38.3% increase in prescription (Rx) business and a 71.4% surge in digital services.

The company's adjusted EBITDA improved by CHF 17.9 million compared to the previous year, reaching minus CHF 10.9 million. Management expressed confidence in reaching EBITDA breakeven during the second half of 2026. The improved outlook for adjusted EBITDA is now set between a loss of CHF 10 million and CHF 17.5 million, an improvement from previous estimates of up to CHF 25 million in losses.

Following the announcement, DocMorris shares saw positive movement on various trading platforms, including Tradegate and SIX. While the company noted increased extraordinary costs related to its ‘AI-First’ strategy and restructuring, such as the closure of a location in Ludwigshafen, management expects these to be offset by cost savings in the latter half of the year.